US20190275012A9 - Substituted thiazolo-pyridine compounds as malt1 inhibitors - Google Patents

Substituted thiazolo-pyridine compounds as malt1 inhibitors Download PDF

Info

Publication number
US20190275012A9
US20190275012A9 US16/320,902 US201716320902A US2019275012A9 US 20190275012 A9 US20190275012 A9 US 20190275012A9 US 201716320902 A US201716320902 A US 201716320902A US 2019275012 A9 US2019275012 A9 US 2019275012A9
Authority
US
United States
Prior art keywords
pyridin
compound
urea
methylthiazolo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/320,902
Other languages
English (en)
Other versions
US20190160045A1 (en
Inventor
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P. Palle
Rajender Kumar Kamboj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of US20190160045A1 publication Critical patent/US20190160045A1/en
Assigned to LUPIN LIMITED reassignment LUPIN LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DESHMUKH, GOKUL KERUJI, IRLAPATI, NAGESWARA RAO, JAGDALE, ARUN RANGNATH, KAMBOJ, RAJENDER KUMAR, KUKREJA, GAGAN, KULKARNI, KIRAN CHANDRASHEKHAR, PALLE, VENKATA P., SINHA, NEELIMA, VYAVAHARE, VINOD POPATRAO
Publication of US20190275012A9 publication Critical patent/US20190275012A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
US16/320,902 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors Abandoned US20190275012A9 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29
IN201621026107 2016-07-29
IN201621043859 2016-12-22
IN201621043859 2016-12-22
IN201721009450 2017-03-17
IN201721009450 2017-03-17
PCT/IB2017/054612 WO2018020474A1 (fr) 2016-07-29 2017-07-28 Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/054612 A-371-Of-International WO2018020474A1 (fr) 2016-07-29 2017-07-28 Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/831,301 Continuation US20210052556A1 (en) 2016-07-29 2020-03-26 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Publications (2)

Publication Number Publication Date
US20190160045A1 US20190160045A1 (en) 2019-05-30
US20190275012A9 true US20190275012A9 (en) 2019-09-12

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/320,902 Abandoned US20190275012A9 (en) 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Country Status (15)

Country Link
US (1) US20190275012A9 (fr)
JP (1) JP2019522035A (fr)
KR (1) KR20190033607A (fr)
CN (1) CN110312724A (fr)
AU (1) AU2017302182B2 (fr)
CA (1) CA3032334A1 (fr)
CL (1) CL2019000221A1 (fr)
DO (1) DOP2019000020A (fr)
IL (1) IL289474A (fr)
MX (1) MX2019001132A (fr)
PE (1) PE20190656A1 (fr)
PH (1) PH12019500214A1 (fr)
RU (1) RU2019104890A (fr)
SG (1) SG11201900745VA (fr)
WO (1) WO2018020474A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248007B2 (en) 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof
WO2019099307A1 (fr) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Dérivés d'urée utilisés en tant qu'inhibiteurs d'ask1
EA202092962A1 (ru) * 2018-06-18 2021-09-06 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
ES2966457T3 (es) * 2018-06-18 2024-04-22 Janssen Pharmaceutica Nv Derivados de pirazol como inhibidores de MALT1
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
JP6972384B2 (ja) 2018-11-28 2021-11-24 武田薬品工業株式会社 複素環化合物
CA3131856A1 (fr) 2019-04-11 2020-10-15 Janssen Pharmaceutica N.V. Cycles pyridine contenant des derives servant d'inhibiteurs de malt1
TW202115077A (zh) * 2019-07-01 2021-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｍａｌｔ１抑制劑及其用途
WO2021063735A1 (fr) * 2019-10-02 2021-04-08 Basf Se Nouveaux dérivés pyridines bicycliques
AU2020413333A1 (en) * 2019-12-27 2022-06-16 Schrödinger, Inc. Cyclic compounds and methods of using same
US20230192685A1 (en) * 2020-05-27 2023-06-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
EP4243812A1 (fr) * 2020-11-12 2023-09-20 Monopteros Therapeutics, Inc. Matériaux et procédés de traitement du cancer
WO2023148501A1 (fr) 2022-02-03 2023-08-10 C4X Discovery Limited Dérivés hétérocycliques en tant qu'inhibiteurs de malt1
WO2023192506A1 (fr) * 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Modulateurs de malt1 et leurs utilisations
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
KR20020050257A (ko) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃａｔ 저해제에 의한 플라크 파열의 방지
WO2003090746A1 (fr) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles utilises en tant que modulateurs du lxr pour le traitement de maladies cardiovasculaires
WO2008146259A2 (fr) 2007-06-01 2008-12-04 University Of Lausanne Clivage spécifique de malt1 dans un procédé de dosage et de criblage
EP2222326B2 (fr) 2007-11-21 2015-02-25 Vib Vzw Inhibiteurs d'activité protéolytique de malt1 et leur utilisations
BR112014001714A2 (pt) * 2011-07-26 2017-02-14 Gruenenthal Gmbh derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
AU2012292016B2 (en) * 2011-08-02 2017-06-01 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Selective inhibition MALT1 protease by phenothiazine derivatives
WO2013053765A1 (fr) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. Modèle animal non humain de lymphome du tissu lymphoïde associé aux muqueuses (malt)
EP2916656B1 (fr) 2012-11-09 2017-10-25 Cornell University Inhibiteurs de malt1 à petites molécules
WO2014086478A1 (fr) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibiteurs de la protéase malt1
ES2909438T3 (es) 2013-06-26 2022-05-06 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Enantiómero (S) de mepacina como inhibidor de paracaspasa (MALT1) para tratar cáncer
EP3097124B1 (fr) 2014-01-21 2018-12-19 Helmholtz Zentrum München Moyens et procédés de détection de malt1 activé
SI3149001T1 (sl) * 2014-05-28 2019-08-30 Novartis Ag Novi derivati pirazolo pirimidina in njihova uporaba kot inhimitorji malt1
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
EP3341007B1 (fr) 2015-08-28 2020-12-23 Cornell University Inhibiteurs de malt1 et leurs utilisations
WO2017057695A1 (fr) 2015-09-30 2017-04-06 東レ株式会社 Dérivé de diphénylpyrazol et son utilisation à des fins médicales
CN108473499B (zh) 2015-11-13 2021-07-23 诺华股份有限公司 新颖的吡唑并嘧啶衍生物
US11248007B2 (en) * 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof

Also Published As

Publication number Publication date
DOP2019000020A (es) 2019-04-30
PH12019500214A1 (en) 2019-10-28
JP2019522035A (ja) 2019-08-08
AU2017302182B2 (en) 2021-11-04
PE20190656A1 (es) 2019-05-08
AU2017302182A1 (en) 2019-03-07
CN110312724A (zh) 2019-10-08
CA3032334A1 (fr) 2018-02-01
RU2019104890A (ru) 2020-08-31
RU2019104890A3 (fr) 2020-08-31
MX2019001132A (es) 2019-12-16
SG11201900745VA (en) 2019-02-27
CL2019000221A1 (es) 2019-06-07
US20190160045A1 (en) 2019-05-30
IL289474A (en) 2022-02-01
WO2018020474A1 (fr) 2018-02-01
KR20190033607A (ko) 2019-03-29

Similar Documents

Publication Publication Date Title
AU2017302182B2 (en) Substituted thiazolo-pyridine compounds as MALT1 inhibitors
US9969731B2 (en) Heterocyclyl compounds as MEK inhibitors
US10052330B2 (en) Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
CA3047106A1 (fr) Composes d'aminothiazole en tant qu'inhibiteurs de c-kit
US20180230157A1 (en) PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
US20070066624A1 (en) Chemokine receptor binding compounds
KR20150069011A (ko) 치환된 벤젠 화합물
US20160024021A1 (en) Novel pyrimidine and pyridine compounds and their usage
US20210284624A1 (en) Immunomodulatory compounds
US20100298366A1 (en) Chemokine receptor binding compounds
TW202210466A (zh) 治療性化合物
US20210230148A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
US10961238B2 (en) Modulators of hedgehog (Hh) signaling pathway
US9975888B2 (en) Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US20210052556A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
KR20230058655A (ko) 단백질 분비 억제제
US20240158415A1 (en) Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2024011116A2 (fr) Inhibiteurs irréversibles puissants et sélectifs d'irak1

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: LUPIN LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUKREJA, GAGAN;IRLAPATI, NAGESWARA RAO;JAGDALE, ARUN RANGNATH;AND OTHERS;REEL/FRAME:049328/0399

Effective date: 20170802

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE